Helex, a therapeutics startup developing a new class of targeted medicines for genetic kidney diseases, has raised $3.5 million in a seed funding round led by pi Ventures, along with participation from Bluehill Capital, SOSV, and a global syndicate of investors.<\/p>\n
With this round, Helex has raised over $6 million in total funding to date. The proceeds will be used to accelerate its lead candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) while advancing its platform to establish a differentiated kidney therapeutics portfolio, Helex said in a press release.<\/p>\n
Co-founded in 2021 by Poulami Chaudhuri, Rohini Kalvakuntla, and Anirudh Nishtala, Helex is a therapeutics company developing a new class of targeted medicines for genetic kidney diseases using its proprietary LNP drug delivery and AI-based drug design platforms.<\/p>\n
Incubated at ASPIRE-BioNEST, University of Hyderabad, Helex aims to bring a paradigm shift in the treatment of chronic and rare kidney disorders by developing programmable, non-viral LNP therapeutics that deliver genetic payloads directly to kidney cells.<\/p>\n
According to Helex, its platform is powered by data-driven deep learning modeling using its own genomics data, bioinformatics, and high-throughput sequencing data from gene-edited target cells to create, verify, and deliver disease-specific gRNA.<\/p>\n
Helex says that its lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a progressive inherited disorder affecting more than 12 million people globally and nearly 5% of Chronic Kidney Disease (CKD) patients in India. It aims to change that with a single-dose, non-viral, gene-editing-based therapy that could halt or significantly slow disease progression.<\/p>\n
Disclaimer:<\/p>\n
Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever. You may find a list of our investors here<\/a>.<\/p>\n
![\"banner\"\/](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/07\/zG8sbRMt5HG04yMhLVd2.webp.webp\")
<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Helex, a therapeutics startup developing a new class of targeted medicines for genetic kidney diseases, has raised $3.5…\n","protected":false},"author":2,"featured_media":262789,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[64,63,99,198,154133],"class_list":{"0":"post-262788","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-entrepreneurship","8":"tag-au","9":"tag-australia","10":"tag-business","11":"tag-entrepreneurship","12":"tag-helex"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/262788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=262788"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/262788\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/262789"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=262788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=262788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=262788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}